Cell and Gene Therapy Manufacturing Services Market Size, Share, and Outlook, H2-2025 Report- By Type (Cell Therapy, Gene Therapy), By Indication (Oncology, Cardiovascular, Orthopedic, Ophthalmology, Central Nervous System, Infectious Diseases, Others), B
Description
Cell and Gene Therapy Manufacturing Services Market Outlook
The global Cell and Gene Therapy Manufacturing Services Market Size is valued at $14.8 Billion in 2025 and is forecast to reach $57.2 Billion in 2032 at a CAGR of 21.3%.
The Cell and Gene Therapy Manufacturing Services Market continue to remain a steadily growing market and offers lucrative growth opportunities across the industry stakeholders from suppliers to distributors and end-use industries. This comprehensive market research report provides 12-year historic and forecast data on Cell and Gene Therapy Manufacturing Services Market segments across 22 countries from 2021 to 2032. Key segments covered include By Type (Cell Therapy, Gene Therapy), By Indication (Oncology, Cardiovascular, Orthopedic, Ophthalmology, Central Nervous System, Infectious Diseases, Others), By Application (Clinical Manufacturing, Commercial Manufacturing), By End-User (Pharmaceutical & Biotechnology Companies, Academic & Research Institutes, Others), offering granular insights into performance drivers and emerging patterns. With over 70 tables and charts, the report provides actionable findings based on extensive data modeling and industry surveys.
Cell and Gene Therapy Manufacturing Services Market Insights, 2025
The cell and gene therapy manufacturing services market is at the forefront of biopharmaceutical innovation, supporting the production of cutting-edge treatments for cancer, rare genetic disorders, and other life-threatening conditions. These services cover process development, vector manufacturing, cell expansion, purification, and fill-finish operations, all under stringent GMP compliance. With the growing number of approved cell and gene therapies, biopharma companies are increasingly outsourcing manufacturing to specialized contract development and manufacturing organizations (CDMOs) to overcome capacity constraints and regulatory complexities. Advanced manufacturing technologies, including closed-system automation and real-time quality analytics, are enhancing scalability and reducing production costs. The expansion of global manufacturing networks and partnerships between therapy developers and CDMOs is enabling faster commercialization timelines. Furthermore, ongoing investments in modular facilities and regional production hubs are addressing supply chain challenges and improving patient access to these transformative therapies.
Five Trends Shaping the Global Cell and Gene Therapy Manufacturing Services Market in 2025 and Beyond
The global Cell and Gene Therapy Manufacturing Services Industry is undergoing a paradigm shift driven by regulatory changes, technological innovation, and sustainability imperatives. Amidst intense demand growth from diverse end-users, companies are focusing on new product launches to cater to individual applications. Companies are also emphasizing operational resilience and circular economy principles and are aligning strategies to secure long-term growth. The report identifies key structural changes, disruptive technologies, and evolving trade flows influencing competitiveness, helping stakeholders strengthen decision-making for both the short and long term.
What are the Biggest Opportunities for Growth in the Cell and Gene Therapy Manufacturing Services Industry?
The Cell and Gene Therapy Manufacturing Services Market sector has shown strong adaptability amid volatility in prices, supply chain disruptions, and geopolitical tensions. Moving forward, potential opportunities lie in niche products, aggressive distribution activities, and digital process optimization. With increasing demand from emerging markets, Cell and Gene Therapy Manufacturing Services Market is positioned for growth through 2030 and beyond. This chapter provides a strategic perspective for businesses to identify revenue-generating avenues, mitigate risks, and adopt innovative pathways for expansion.
Cell and Gene Therapy Manufacturing Services Market Segment Insights
The Cell and Gene Therapy Manufacturing Services Industry offers diverse opportunities across product types, applications, and distribution channels. The analytical report provides detailed forecasts across diverse segments including By Type (Cell Therapy, Gene Therapy), By Indication (Oncology, Cardiovascular, Orthopedic, Ophthalmology, Central Nervous System, Infectious Diseases, Others), By Application (Clinical Manufacturing, Commercial Manufacturing), By End-User (Pharmaceutical & Biotechnology Companies, Academic & Research Institutes, Others). Insights cover the largest and fastest-growing product types, applications, and regions, highlighting drivers behind each segment. Market outlooks are provided for five regions—Asia Pacific, North America, Europe, South America, and Middle East & Africa—with country-level forecasts for 22 markets through 2032.
Cell and Gene Therapy Manufacturing Services Industry Value Chain
The chapter identifies potential companies and their operations across the global Cell and Gene Therapy Manufacturing Services Industry ecosystem. It assists decision-makers in evaluating global Cell and Gene Therapy Manufacturing Services Market fundamentals, market dynamics, and disruptive trends across the value chain segments. According to the International Council of Chemical Associations (ICCA), chemicals underpin over 95% of manufactured products worldwide.
Scenario Analysis and Forecasts
Strategic planning in the Cell and Gene Therapy Manufacturing Services Industry requires resilience to uncertain macroeconomic and regulatory conditions. To guide stakeholders, the report offers three scenario forecasts—low growth, reference case, and high growth—enabling companies to align strategies under different market conditions.
Asia Pacific Cell and Gene Therapy Manufacturing Services Market Analysis – Hub of Industrial Transformation
Asia Pacific continues to be the largest and fastest-growing region for Cell and Gene Therapy Manufacturing Services Market, underpinned by rapid industrialization, large-scale infrastructure development, and rising consumption across emerging economies. China, India, and Southeast Asia lead the demand surge, supported by investments in chemical parks, free trade agreements, and rising domestic manufacturing capacity. China remains the single largest producer and consumer of chemicals, accounting for over $1.5 trillion in chemical sales, followed by India, which is projected by the India Brand Equity Foundation (IBEF) to become a $300 billion chemicals market by 2025. Further, Japanese and South Korean markets remain stable with most companies focusing on new product launches and diversification of sales channels.
United States Cell and Gene Therapy Manufacturing Services Market Insights – Innovation and Specialty Leadership
The American Chemistry Council (ACC) projects steady annual demand growth for specialty and performance chemicals, particularly in automotive, electronics, agriculture, and construction applications. The US continues to lead in specialty and high-value-added chemicals, with investments focused on R&D, advanced process technologies, and digital manufacturing. In addition, the Canadian and Mexican markets offer lucrative growth pockets for manufacturers and vendors. Focus on private-brand offerings and promotions, diversified sales channels, expansion into niche segments, adoption of advanced technologies, and sustainability are widely observed across the North American Cell and Gene Therapy Manufacturing Services Market.
Europe Cell and Gene Therapy Manufacturing Services Market Outlook 2025 – Regulatory and Innovation-Driven Growth
Europe is one of the largest markets for Cell and Gene Therapy Manufacturing Services Market with demand from both Western Europe and Eastern European regions increasing over the medium to long-term future. The European chemical sector employs more than 1.2 million people directly and is highly influenced by the EU Green Deal, which aims for climate neutrality by 2050. With increasing adoption of advanced technologies, raw materials, and digital transformation, Europe remains a strategic hub for Cell and Gene Therapy Manufacturing Services Industry competitiveness. The report analyses the key Cell and Gene Therapy Manufacturing Services Market drivers and opportunities across Germany, France, the United Kingdom, Spain, Italy, Russia, and other Europe.
Latin American Cell and Gene Therapy Manufacturing Services Market outlook rebounds in line with economic growth
Optimistic economic outlook across Brazil, Argentina, Chile, and other South and Central American countries presents strong opportunities for domestic and international Cell and Gene Therapy Manufacturing Services Market companies. Increased consumer spending is estimated across markets over the next few quarters through 2026. Expanding trade partnerships, urbanization, and growing demand for specialty products underpin market prospects.
Middle East and Africa Cell and Gene Therapy Manufacturing Services Markets- New Opportunities for Companies Harnessing Diversity
The Middle East remains a key hub for Cell and Gene Therapy Manufacturing Services Market companies, with Saudi Arabia, UAE, and Qatar investing heavily in distribution networks. In addition, Africa presents strong growth potential in Nigeria, South Africa, and other emerging economies, with increasing demand for cost effective and accessible products. Investment strategies tailored to localized needs and sustainable growth will be crucial for success. In addition to Nigeria, Algeria, South Africa, and other markets, steady growth markets in Ethiopia, Rwanda, Ghana, Tanzania, the Democratic Republic of Congo, and others present significant prospects for companies.
Competitive Landscape – How Cell and Gene Therapy Manufacturing Services Market Companies Outcompete in 2025
The ability to adapt to changing regulations, sustainability imperatives, and customer-specific innovations defines leadership in the Cell and Gene Therapy Manufacturing Services Market. Companies are leveraging M&A activities, strategic joint ventures, and vertical integration to secure raw material access and strengthen downstream presence. The report profiles leading players, analyzing their 2024 revenues, market shares, R&D expenditures, and strategic directions. The report analyzes ABL Inc, Andelyn Biosciences LLC, Anemocyte Srl, BioCentriq LLC, Catalent Inc, Cell and Gene Therapy Catapult, Charles River Laboratories International Inc, ElevateBio Holdings Inc, FinVector Oy, Forge Biologics Inc, FUJIFILM Holdings Corp, Genezen Laboratories Ltd, JRS Pharma LP, Lonza Group Ltd, Merck KGaA, Nikon Corp, Oxford Biomedica plc, Porton Advanced Solutions Ltd, Resilience Corp, RoslinCT , Takara Bio Inc, The Discovery Labs LLC, Thermo Fisher Scientific Inc, Vibalogics GmbH, WuXi AppTec Co. Ltd. Each company is benchmarked through a detailed SWOT and financial analysis, providing clients with insights into competitive positioning and innovation leadership.
Cell and Gene Therapy Manufacturing Services Market Scope
Leading Segments
By Type
Cell TherapyAllogeneic Autologous Viral Vector
Gene TherapyViral Vector Non-viral Vector
By Indication
Oncology
Cardiovascular
Orthopedic
Ophthalmology
Central Nervous System
Infectious Diseases
Others
By Application
Clinical Manufacturing
Commercial Manufacturing
By End-User
Pharmaceutical & Biotechnology Companies
Academic & Research Institutes
Others
Leading Companies
ABL Inc
Andelyn Biosciences LLC
Anemocyte Srl
BioCentriq LLC
Catalent Inc
Cell and Gene Therapy Catapult
Charles River Laboratories International Inc
ElevateBio Holdings Inc
FinVector Oy
Forge Biologics Inc
FUJIFILM Holdings Corp
Genezen Laboratories Ltd
JRS Pharma LP
Lonza Group Ltd
Merck KGaA
Nikon Corp
Oxford Biomedica plc
Porton Advanced Solutions Ltd
Resilience Corp
RoslinCT
Takara Bio Inc
The Discovery Labs LLC
Thermo Fisher Scientific Inc
Vibalogics GmbH
WuXi AppTec Co. Ltd
Geographies
North America- US, Canada, Mexico
Europe- Germany, France, UK, Spain, Italy, Nordics, BeNeLux, Others
Asia Pacific- China, India, Japan, South Korea, Australia, South East Asia, Others
Latin America- Brazil, Argentina, Others
Middle East and Africa- Saudi Arabia, UAE, Other Middle East, South Africa, Other Africa
Reasons to Buy the Report Make informed decisions with 12-year forecasts across 22 countries and multiple market segments. Evaluate regulatory impacts, sustainability trends, and disruptive technologies shaping the chemicals industry. Gain insights into the competitive landscape, including company profiles, financials, and strategic moves. Build an integrated understanding of the chemicals ecosystem across upstream, midstream, and downstream operations. Leverage insights on circular economy initiatives, digitalization, and carbon-neutral strategies driving the next decade. Assess risks and opportunities with scenario-based forecasts tailored to different growth conditions. Access the report in multiple formats (PDF, Excel, PPT) for easier integration into strategic planning.
The global Cell and Gene Therapy Manufacturing Services Market Size is valued at $14.8 Billion in 2025 and is forecast to reach $57.2 Billion in 2032 at a CAGR of 21.3%.
The Cell and Gene Therapy Manufacturing Services Market continue to remain a steadily growing market and offers lucrative growth opportunities across the industry stakeholders from suppliers to distributors and end-use industries. This comprehensive market research report provides 12-year historic and forecast data on Cell and Gene Therapy Manufacturing Services Market segments across 22 countries from 2021 to 2032. Key segments covered include By Type (Cell Therapy, Gene Therapy), By Indication (Oncology, Cardiovascular, Orthopedic, Ophthalmology, Central Nervous System, Infectious Diseases, Others), By Application (Clinical Manufacturing, Commercial Manufacturing), By End-User (Pharmaceutical & Biotechnology Companies, Academic & Research Institutes, Others), offering granular insights into performance drivers and emerging patterns. With over 70 tables and charts, the report provides actionable findings based on extensive data modeling and industry surveys.
Cell and Gene Therapy Manufacturing Services Market Insights, 2025
The cell and gene therapy manufacturing services market is at the forefront of biopharmaceutical innovation, supporting the production of cutting-edge treatments for cancer, rare genetic disorders, and other life-threatening conditions. These services cover process development, vector manufacturing, cell expansion, purification, and fill-finish operations, all under stringent GMP compliance. With the growing number of approved cell and gene therapies, biopharma companies are increasingly outsourcing manufacturing to specialized contract development and manufacturing organizations (CDMOs) to overcome capacity constraints and regulatory complexities. Advanced manufacturing technologies, including closed-system automation and real-time quality analytics, are enhancing scalability and reducing production costs. The expansion of global manufacturing networks and partnerships between therapy developers and CDMOs is enabling faster commercialization timelines. Furthermore, ongoing investments in modular facilities and regional production hubs are addressing supply chain challenges and improving patient access to these transformative therapies.
Five Trends Shaping the Global Cell and Gene Therapy Manufacturing Services Market in 2025 and Beyond
The global Cell and Gene Therapy Manufacturing Services Industry is undergoing a paradigm shift driven by regulatory changes, technological innovation, and sustainability imperatives. Amidst intense demand growth from diverse end-users, companies are focusing on new product launches to cater to individual applications. Companies are also emphasizing operational resilience and circular economy principles and are aligning strategies to secure long-term growth. The report identifies key structural changes, disruptive technologies, and evolving trade flows influencing competitiveness, helping stakeholders strengthen decision-making for both the short and long term.
What are the Biggest Opportunities for Growth in the Cell and Gene Therapy Manufacturing Services Industry?
The Cell and Gene Therapy Manufacturing Services Market sector has shown strong adaptability amid volatility in prices, supply chain disruptions, and geopolitical tensions. Moving forward, potential opportunities lie in niche products, aggressive distribution activities, and digital process optimization. With increasing demand from emerging markets, Cell and Gene Therapy Manufacturing Services Market is positioned for growth through 2030 and beyond. This chapter provides a strategic perspective for businesses to identify revenue-generating avenues, mitigate risks, and adopt innovative pathways for expansion.
Cell and Gene Therapy Manufacturing Services Market Segment Insights
The Cell and Gene Therapy Manufacturing Services Industry offers diverse opportunities across product types, applications, and distribution channels. The analytical report provides detailed forecasts across diverse segments including By Type (Cell Therapy, Gene Therapy), By Indication (Oncology, Cardiovascular, Orthopedic, Ophthalmology, Central Nervous System, Infectious Diseases, Others), By Application (Clinical Manufacturing, Commercial Manufacturing), By End-User (Pharmaceutical & Biotechnology Companies, Academic & Research Institutes, Others). Insights cover the largest and fastest-growing product types, applications, and regions, highlighting drivers behind each segment. Market outlooks are provided for five regions—Asia Pacific, North America, Europe, South America, and Middle East & Africa—with country-level forecasts for 22 markets through 2032.
Cell and Gene Therapy Manufacturing Services Industry Value Chain
The chapter identifies potential companies and their operations across the global Cell and Gene Therapy Manufacturing Services Industry ecosystem. It assists decision-makers in evaluating global Cell and Gene Therapy Manufacturing Services Market fundamentals, market dynamics, and disruptive trends across the value chain segments. According to the International Council of Chemical Associations (ICCA), chemicals underpin over 95% of manufactured products worldwide.
Scenario Analysis and Forecasts
Strategic planning in the Cell and Gene Therapy Manufacturing Services Industry requires resilience to uncertain macroeconomic and regulatory conditions. To guide stakeholders, the report offers three scenario forecasts—low growth, reference case, and high growth—enabling companies to align strategies under different market conditions.
Asia Pacific Cell and Gene Therapy Manufacturing Services Market Analysis – Hub of Industrial Transformation
Asia Pacific continues to be the largest and fastest-growing region for Cell and Gene Therapy Manufacturing Services Market, underpinned by rapid industrialization, large-scale infrastructure development, and rising consumption across emerging economies. China, India, and Southeast Asia lead the demand surge, supported by investments in chemical parks, free trade agreements, and rising domestic manufacturing capacity. China remains the single largest producer and consumer of chemicals, accounting for over $1.5 trillion in chemical sales, followed by India, which is projected by the India Brand Equity Foundation (IBEF) to become a $300 billion chemicals market by 2025. Further, Japanese and South Korean markets remain stable with most companies focusing on new product launches and diversification of sales channels.
United States Cell and Gene Therapy Manufacturing Services Market Insights – Innovation and Specialty Leadership
The American Chemistry Council (ACC) projects steady annual demand growth for specialty and performance chemicals, particularly in automotive, electronics, agriculture, and construction applications. The US continues to lead in specialty and high-value-added chemicals, with investments focused on R&D, advanced process technologies, and digital manufacturing. In addition, the Canadian and Mexican markets offer lucrative growth pockets for manufacturers and vendors. Focus on private-brand offerings and promotions, diversified sales channels, expansion into niche segments, adoption of advanced technologies, and sustainability are widely observed across the North American Cell and Gene Therapy Manufacturing Services Market.
Europe Cell and Gene Therapy Manufacturing Services Market Outlook 2025 – Regulatory and Innovation-Driven Growth
Europe is one of the largest markets for Cell and Gene Therapy Manufacturing Services Market with demand from both Western Europe and Eastern European regions increasing over the medium to long-term future. The European chemical sector employs more than 1.2 million people directly and is highly influenced by the EU Green Deal, which aims for climate neutrality by 2050. With increasing adoption of advanced technologies, raw materials, and digital transformation, Europe remains a strategic hub for Cell and Gene Therapy Manufacturing Services Industry competitiveness. The report analyses the key Cell and Gene Therapy Manufacturing Services Market drivers and opportunities across Germany, France, the United Kingdom, Spain, Italy, Russia, and other Europe.
Latin American Cell and Gene Therapy Manufacturing Services Market outlook rebounds in line with economic growth
Optimistic economic outlook across Brazil, Argentina, Chile, and other South and Central American countries presents strong opportunities for domestic and international Cell and Gene Therapy Manufacturing Services Market companies. Increased consumer spending is estimated across markets over the next few quarters through 2026. Expanding trade partnerships, urbanization, and growing demand for specialty products underpin market prospects.
Middle East and Africa Cell and Gene Therapy Manufacturing Services Markets- New Opportunities for Companies Harnessing Diversity
The Middle East remains a key hub for Cell and Gene Therapy Manufacturing Services Market companies, with Saudi Arabia, UAE, and Qatar investing heavily in distribution networks. In addition, Africa presents strong growth potential in Nigeria, South Africa, and other emerging economies, with increasing demand for cost effective and accessible products. Investment strategies tailored to localized needs and sustainable growth will be crucial for success. In addition to Nigeria, Algeria, South Africa, and other markets, steady growth markets in Ethiopia, Rwanda, Ghana, Tanzania, the Democratic Republic of Congo, and others present significant prospects for companies.
Competitive Landscape – How Cell and Gene Therapy Manufacturing Services Market Companies Outcompete in 2025
The ability to adapt to changing regulations, sustainability imperatives, and customer-specific innovations defines leadership in the Cell and Gene Therapy Manufacturing Services Market. Companies are leveraging M&A activities, strategic joint ventures, and vertical integration to secure raw material access and strengthen downstream presence. The report profiles leading players, analyzing their 2024 revenues, market shares, R&D expenditures, and strategic directions. The report analyzes ABL Inc, Andelyn Biosciences LLC, Anemocyte Srl, BioCentriq LLC, Catalent Inc, Cell and Gene Therapy Catapult, Charles River Laboratories International Inc, ElevateBio Holdings Inc, FinVector Oy, Forge Biologics Inc, FUJIFILM Holdings Corp, Genezen Laboratories Ltd, JRS Pharma LP, Lonza Group Ltd, Merck KGaA, Nikon Corp, Oxford Biomedica plc, Porton Advanced Solutions Ltd, Resilience Corp, RoslinCT , Takara Bio Inc, The Discovery Labs LLC, Thermo Fisher Scientific Inc, Vibalogics GmbH, WuXi AppTec Co. Ltd. Each company is benchmarked through a detailed SWOT and financial analysis, providing clients with insights into competitive positioning and innovation leadership.
Cell and Gene Therapy Manufacturing Services Market Scope
Leading Segments
By Type
Cell Therapy
Gene Therapy
By Indication
Oncology
Cardiovascular
Orthopedic
Ophthalmology
Central Nervous System
Infectious Diseases
Others
By Application
Clinical Manufacturing
Commercial Manufacturing
By End-User
Pharmaceutical & Biotechnology Companies
Academic & Research Institutes
Others
Leading Companies
ABL Inc
Andelyn Biosciences LLC
Anemocyte Srl
BioCentriq LLC
Catalent Inc
Cell and Gene Therapy Catapult
Charles River Laboratories International Inc
ElevateBio Holdings Inc
FinVector Oy
Forge Biologics Inc
FUJIFILM Holdings Corp
Genezen Laboratories Ltd
JRS Pharma LP
Lonza Group Ltd
Merck KGaA
Nikon Corp
Oxford Biomedica plc
Porton Advanced Solutions Ltd
Resilience Corp
RoslinCT
Takara Bio Inc
The Discovery Labs LLC
Thermo Fisher Scientific Inc
Vibalogics GmbH
WuXi AppTec Co. Ltd
Geographies
North America- US, Canada, Mexico
Europe- Germany, France, UK, Spain, Italy, Nordics, BeNeLux, Others
Asia Pacific- China, India, Japan, South Korea, Australia, South East Asia, Others
Latin America- Brazil, Argentina, Others
Middle East and Africa- Saudi Arabia, UAE, Other Middle East, South Africa, Other Africa
Reasons to Buy the Report
Table of Contents
192 Pages
- 1. Table of Contents
- List of Figures and Tables
- 2. Executive Summary
- 2.1 Key Highlights
- 2.1.1 Cell and Gene Therapy Manufacturing Services Market Size Outlook, 2018-2024 and 2025-2032
- 2.1.2 Largest Cell and Gene Therapy Manufacturing Services Market Types and Applications
- 2.1.3 Fastest Growing Segments
- 2.1.4 Potential Markets
- 2.1.5 Market Concentration
- 2.2 Market Scope and Segmentation
- 2.2.1 Market Scope- Segments
- 2.2.2 Market Scope- Countries
- 2.2.3 Macroeconomic and Demographic Outlook
- 2.2.4 Abbreviations
- 2.2.5 Units and Currency Conversions
- 3. Research Methodology
- 3.1 Primary Research Surveys
- 3.2 Secondary Data Sources
- 3.3 Data Triangulation
- 3.4 Forecast Methodology
- 3.5 Assumptions and Limitations
- 4. Introduction to Global Cell and Gene Therapy Manufacturing Services Market in 2025
- 4.1 Industry Panorama
- 4.2 Leading Companies Profiled in the Study
- 4.3 Asia Pacific Markets offer Robust Market Prospects for New Entrants
- 4.4 Market Dynamics
- 4.4.1 Market Dynamics- Trends and Drivers
- 4.4.2 Market Dynamics- Opportunities and Challenges
- 4.5 Regional Analysis
- 4.6 Porter’s Five Force Analysis
- 4.6.1 Intensity of Competitive Rivalry
- 4.6.2 Threat of New Entrants
- 4.6.3 Threat of Substitutes
- 4.6.4 Bargaining Power of Buyers
- 4.6.5 Bargaining Power of Suppliers
- 4.7 Cell and Gene Therapy Manufacturing Services Market Industry Value Chain Analysis
- 4.7.1 Stage of Value Chain
- 4.7.2 Key Activities of Companies
- 4.7.3 Companies Included in Each Stage
- 4.7.4 Key Insights
- 5. Cell and Gene Therapy Manufacturing Services Market Outlook to 2032
- 5.1 Market Size Forecast by Type, 2021-2024 and 2025-2032
- 5.2 Market Size Forecast by Application, 2021-2024 and 2024-2032
- 5.3 Market Size Forecast by Geography, 2021-2024 and 2024-2032
- By Type
- Cell Therapy
- -Allogeneic
- -Autologous
- -Viral Vector
- Gene Therapy
- -Viral Vector
- -Non-viral Vector
- By Indication
- Oncology
- Cardiovascular
- Orthopedic
- Ophthalmology
- Central Nervous System
- Infectious Diseases
- Others
- By Application
- Clinical Manufacturing
- Commercial Manufacturing
- By End-User
- Pharmaceutical & Biotechnology Companies
- Academic & Research Institutes
- Others
- 6. Global Cell and Gene Therapy Manufacturing Services Market Outlook across Growth Scenarios
- 6.1 Low Growth Scenario
- 6.2 Base/Reference Case
- 6.3 High Growth Scenario
- 6. North America Cell and Gene Therapy Manufacturing Services Market Size Outlook
- 6.1 Key Market Statistics, 2024
- 6.2 North America Cell and Gene Therapy Manufacturing Services Market Trends and Growth Opportunities
- 6.2.1 North America Cell and Gene Therapy Manufacturing Services Market Outlook by Type
- 6.2.2 North America Cell and Gene Therapy Manufacturing Services Market Outlook by Application
- 6.3 North America Cell and Gene Therapy Manufacturing Services Market Outlook by Country
- 6.3.1 The US Cell and Gene Therapy Manufacturing Services Market Outlook, 2021- 2032
- 6.3.2 Canada Cell and Gene Therapy Manufacturing Services Market Outlook, 2021- 2032
- 6.3.3 Mexico Cell and Gene Therapy Manufacturing Services Market Outlook, 2021- 2032
- 7. Europe Cell and Gene Therapy Manufacturing Services Market Size Outlook
- 7.1 Key Market Statistics, 2024
- 7.2 Europe Cell and Gene Therapy Manufacturing Services Market Trends and Growth Opportunities
- 7.2.1 Europe Cell and Gene Therapy Manufacturing Services Market Outlook by Type
- 7.2.2 Europe Cell and Gene Therapy Manufacturing Services Market Outlook by Application
- 7.3 Europe Cell and Gene Therapy Manufacturing Services Market Outlook by Country
- 7.3.2 Germany Cell and Gene Therapy Manufacturing Services Market Outlook, 2021- 2032
- 7.3.3 France Cell and Gene Therapy Manufacturing Services Market Outlook, 2021- 2032
- 7.3.4 The UK Cell and Gene Therapy Manufacturing Services Market Outlook, 2021- 2032
- 7.3.5 Spain Cell and Gene Therapy Manufacturing Services Market Outlook, 2021- 2032
- 7.3.6 Italy Cell and Gene Therapy Manufacturing Services Market Outlook, 2021- 2032
- 7.3.7 Russia Cell and Gene Therapy Manufacturing Services Market Outlook, 2021- 2032
- 7.3.8 Rest of Europe Cell and Gene Therapy Manufacturing Services Market Outlook, 2021- 2032
- 8. Asia Pacific Cell and Gene Therapy Manufacturing Services Market Size Outlook
- 8.1 Key Market Statistics, 2024
- 8.2 Asia Pacific Cell and Gene Therapy Manufacturing Services Market Trends and Growth Opportunities
- 8.2.1 Asia Pacific Cell and Gene Therapy Manufacturing Services Market Outlook by Type
- 8.2.2 Asia Pacific Cell and Gene Therapy Manufacturing Services Market Outlook by Application
- 8.3 Asia Pacific Cell and Gene Therapy Manufacturing Services Market Outlook by Country
- 8.3.1 China Cell and Gene Therapy Manufacturing Services Market Outlook, 2021- 2032
- 8.3.2 India Cell and Gene Therapy Manufacturing Services Market Outlook, 2021- 2032
- 8.3.3 Japan Cell and Gene Therapy Manufacturing Services Market Outlook, 2021- 2032
- 8.3.4 South Korea Cell and Gene Therapy Manufacturing Services Market Outlook, 2021- 2032
- 8.3.5 Australia Cell and Gene Therapy Manufacturing Services Market Outlook, 2021- 2032
- 8.3.6 South East Asia Cell and Gene Therapy Manufacturing Services Market Outlook, 2021- 2032
- 8.3.7 Rest of Asia Pacific Cell and Gene Therapy Manufacturing Services Market Outlook, 2021- 2032
- 9. South America Cell and Gene Therapy Manufacturing Services Market Size Outlook
- 9.1 Key Market Statistics, 2024
- 9.2 South America Cell and Gene Therapy Manufacturing Services Market Trends and Growth Opportunities
- 9.2.1 South America Cell and Gene Therapy Manufacturing Services Market Outlook by Type
- 9.2.2 South America Cell and Gene Therapy Manufacturing Services Market Outlook by Application
- 9.3 South America Cell and Gene Therapy Manufacturing Services Market Outlook by Country
- 9.3.1 Brazil Cell and Gene Therapy Manufacturing Services Market Outlook, 2021- 2032
- 9.3.2 Argentina Cell and Gene Therapy Manufacturing Services Market Outlook, 2021- 2032
- 9.3.3 Rest of South and Central America Cell and Gene Therapy Manufacturing Services Market Outlook, 2021- 2032
- 10. Middle East and Africa Cell and Gene Therapy Manufacturing Services Market Size Outlook
- 10.1 Key Market Statistics, 2024
- 10.2 Middle East and Africa Cell and Gene Therapy Manufacturing Services Market Trends and Growth Opportunities
- 10.2.1 Middle East and Africa Cell and Gene Therapy Manufacturing Services Market Outlook by Type
- 10.2.2 Middle East and Africa Cell and Gene Therapy Manufacturing Services Market Outlook by Application
- 10.3 Middle East and Africa Cell and Gene Therapy Manufacturing Services Market Outlook by Country
- 10.3.1 Saudi Arabia Cell and Gene Therapy Manufacturing Services Market Outlook, 2021- 2032
- 10.3.2 The UAE Cell and Gene Therapy Manufacturing Services Market Outlook, 2021- 2032
- 10.3.3 Rest of Middle East Cell and Gene Therapy Manufacturing Services Market Outlook, 2021- 2032
- 10.3.4 South Africa Cell and Gene Therapy Manufacturing Services Market Outlook, 2021- 2032
- 10.3.5 Egypt Cell and Gene Therapy Manufacturing Services Market Outlook, 2021- 2032
- 10.3.6 Rest of Africa Cell and Gene Therapy Manufacturing Services Market Outlook, 2021- 2032
- 11. Company Profiles
- 11.1 Leading 10 Companies
- ABL Inc
- Andelyn Biosciences LLC
- Anemocyte Srl
- BioCentriq LLC
- Catalent Inc
- Cell and Gene Therapy Catapult
- Charles River Laboratories International Inc
- ElevateBio Holdings Inc
- FinVector Oy
- Forge Biologics Inc
- FUJIFILM Holdings Corp
- Genezen Laboratories Ltd
- JRS Pharma LP
- Lonza Group Ltd
- Merck KGaA
- Nikon Corp
- Oxford Biomedica plc
- Porton Advanced Solutions Ltd
- Resilience Corp
- RoslinCT
- Takara Bio Inc
- The Discovery Labs LLC
- Thermo Fisher Scientific Inc
- Vibalogics GmbH
- WuXi AppTec Co. Ltd
- 11.2 Overview
- 11.3 Products and Services
- 11.4 SWOT Profile
- 12. Appendix
- 12.1 Subscription Options
- 12.2 Customization Options
- 12.3 Publisher Details
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
